AFT Pharmaceuticals Ltd represents core values of innovation, integrity, and excellence. As a leading pharmaceutical company, they prioritize the development of cutting-edge and high-quality healthcare products. With a strong commitment to improving patients' lives, AFT Pharmaceuticals aims to deliver innovative solutions to meet their needs. They believe in maintaining the highest standards of integrity, transparency, and ethical conduct in all their business practices. With a focus on research and development, AFT Pharmaceuticals continually strives for excellence in producing novel and effective medicines. Through their dedication, AFT Pharmaceuticals aims to make a positive impact on the healthcare industry and contribute to the well-being of individuals worldwide.

AFT Pharmaceuticals Ltd is primarily present in various countries and regions worldwide. The company operates in Australia, New Zealand, Southeast Asia, and the Middle East. With a strong presence in these markets, AFT Pharmaceuticals is committed to delivering innovative healthcare solutions and improving patient outcomes. As a leading pharmaceutical company, AFT Pharmaceuticals continues to expand its global footprint, ensuring access to their high-quality products across different regions.

AFT Pharmaceuticals Ltd has achieved several significant milestones. The company successfully listed on the Australian Securities Exchange (ASX) in December 2015, expanding its investor base. In 2017, AFT Pharmaceuticals launched its patented painkiller, Maxigesic, in the United States, marking an important entry into the large American pharmaceutical market. The company has also expanded its product portfolio with the launch of Crystawash, a preservative-free eye drop for dry eyes. Furthermore, AFT Pharmaceuticals has established partnerships with global pharmaceutical companies for the commercialization of its products in various countries. These milestones demonstrate the company's growth, market penetration, and commitment to developing innovative healthcare solutions.

AFT Pharmaceuticals Ltd is a pharmaceuticals company based in New Zealand that specializes in developing and marketing a wide range of pharmaceutical products. Established in 1997 by Dr. Hartley Atkinson, AFT Pharmaceuticals has gained significant recognition in the healthcare industry. With a strong focus on research and development, they have successfully launched innovative products in various therapeutic areas. AFT Pharmaceuticals is dedicated to improving patient care and providing access to quality medications. Over the years, the company has expanded its market presence globally, establishing partnerships and subsidiaries in multiple countries. AFT Pharmaceuticals Ltd has a strong history of delivering high-quality pharmaceutical solutions to meet the needs of patients worldwide.

The main competitors of AFT Pharmaceuticals Ltd in the market include other pharmaceutical companies such as Pfizer, Johnson & Johnson, Novartis, and GlaxoSmithKline. These companies also operate in the pharmaceutical industry and offer a range of products and services that compete with AFT Pharmaceuticals Ltd's offerings.

AFT Pharmaceuticals Ltd is primarily active in the pharmaceutical industry.

The business model of AFT Pharmaceuticals Ltd revolves around the development, manufacturing, and marketing of pharmaceutical products. With a focus on both prescription and over-the-counter healthcare solutions, AFT Pharmaceuticals aims to improve patient outcomes and access to high-quality medicines. The company strategically targets therapeutic areas such as pain management, respiratory diseases, and allergies. By continuously innovating and leveraging its strong research and development capabilities, AFT Pharmaceuticals seeks to provide effective and affordable healthcare options for patients worldwide.

AFT Pharmaceuticals P/E suhe on 20,63.

AFT Pharmaceuticals KUV on 1,65.

AlleAktien kvaliteediskoor ettevõttele AFT Pharmaceuticals on 7/10.

AFT Pharmaceuticals käive on 195,41 mln. NZD.

AFT Pharmaceuticals kasum on 15,61 mln. NZD.

AFT Pharmaceuticals Ltd is a New Zealand-based company that specializes in the development, manufacturing, and marketing of pharmaceuticals. The company's business model is based on innovation, efficiency, and customer-centricity. AFT Pharmaceuticals operates in various markets, including New Zealand, Australia, and Asia. Its product portfolio includes a wide range of prescription and non-prescription drugs, such as analgesics, anti-rheumatics, allergy relief products, cough and cold remedies, eye drops, dermatology products, and antidepressants. These drugs are distributed through various channels, including pharmacies, retailers, and hospitals. The company follows a vertical integration approach, with its own manufacturing and development department. This allows for efficient production and quick market introduction of new products. The drug development process includes research and development, clinical trials and approval, packaging, and marketing. This model helps AFT Pharmaceuticals differentiate itself from competitors and strengthen its market position. Additionally, the company is involved in researching medications for high-demand diseases, such as cancer and neurodegenerative disorders. AFT Pharmaceuticals aims to develop new treatment approaches that positively impact patients' quality of life. A key pillar of AFT Pharmaceuticals' business model is partnering with other pharmaceutical companies. The company has entered into distribution agreements with global pharmaceutical companies to support product distribution in different regions. This collaboration provides AFT Pharmaceuticals with additional resources and allows it to focus on core competencies like research and development. The company is also committed to increasing customer satisfaction and improving customer interaction. AFT Pharmaceuticals has developed an extensive customer training program to ensure proper product application and achieve the best possible outcomes. Furthermore, the company has established a dedicated customer service team to assist customers with questions and concerns. In summary, AFT Pharmaceuticals' business model is focused on innovation, efficiency, and customer benefit. The company follows a vertically integrated strategy that encompasses the manufacturing, development, and marketing of pharmaceuticals. Partnerships with other pharmaceutical companies provide additional resources and global market access. With its wide product range and commitment to customer satisfaction, AFT Pharmaceuticals is well-positioned to grow in the pharmaceutical industry.

AFT Pharmaceuticals maksab dividendi 0 NZD, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu AFT Pharmaceuticals jaoks arvutada või ettevõte ei maksa dividende välja.

AFT Pharmaceuticals ISIN on NZAFTE0001S4.

AFT Pharmaceuticals WKN on A2DVUC.

AFT Pharmaceuticals tähis on AFT.NZ.

Viimase 12 kuu jooksul maksis AFT Pharmaceuticals dividendi suuruses 0,02 NZD . See vastab ligikaudu 0,52 % dividenditootlusele. Järgneva 12 kuu jooksul maksab AFT Pharmaceuticals tõenäoliselt dividendi summas 0,02 NZD.

AFT Pharmaceuticals praegune dividenditootlus on 0,52 %.

AFT Pharmaceuticals maksab kvartaalset dividendi. See makstakse välja kuudel .

AFT Pharmaceuticals maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0,02 NZD. See vastab dividenditootlusele 0,52 %.

AFT Pharmaceuticals on liigitatud sektorisse 'Tervis'.

Viimase AFT Pharmaceuticals dividendide saamiseks 4.7.2024 suuruses 0,016 NZD pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 19.6.2024.

Viimane dividendimakse toimus 4.7.2024.

Aastal 2023 maksis AFT Pharmaceuticals 0,011 NZD dividende.

AFT Pharmaceuticals dividendid makstakse välja NZD.